Kojin: Kojin Therapeutics Launches with $60 Million Series A to Develop New Category of Drugs Based on Cell State Biology

Kojin Therapeutics Inc., the leading company developing new targeted therapeutics based on cell state and ferroptosis biology, launched with a $60 million Series A led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital, with participation from Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute's Binney Street Capital, and several family offices.